Prospects of Disease-Modifying Osteoarthritis Drugs

被引：4
作者：
Oo, Win Min [1 ,2 ]
机构：
[1] Univ Med, Mandalay Gen Hosp, Dept Phys Med & Rehabil, Mandalay, Mandalay, Myanmar
[2] Univ Sydney, Royal North Shore Hosp, Inst Bone & Joint Res, Kolling Inst,Rheumatol Dept, Sydney, Australia
来源：
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2024年 / 50卷 / 03期
关键词：
Osteoarthritis; DMOADs; Disease-modifying drugs; Intra-articular therapy; endotype; BONE-MARROW LESIONS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REDUCES CARTILAGE LOSS; POST-HOC ANALYSIS; GROWTH-FACTOR; 18; KNEE OSTEOARTHRITIS; INTRAARTICULAR SPRIFERMIN; CATHEPSIN K; SUBCHONDRAL BONE; CLINICAL-TRIALS;
D O I：
10.1016/j.rdc.2024.03.003
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：483 / 518
页数：36
相关论文
共 141 条
  • [1] AgencyEM, 2014, PRAC re-examines diacerein and recommends that it remain avail- able with restrictions
  • [2] Clinical benefit of intra-articular saline as a comparator in clinical trials of knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials
    Altman, Roy D.
    Devji, Tahira
    Bhandari, Mohit
    Fierlinger, Anke
    Niazi, Faizan
    Christensen, Robin
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (02) : 151 - 159
  • [3] [Anonymous], 2020, The pharma letter
  • [4] [Anonymous], 2020, UnityBiotechnology I. UNITY biotechnology announces 12-week data from UBX0101 phase 2 clinical study in patients with painful osteoarthritis of the knee
  • [5] [Anonymous], 2020, Galapagos and Servier report topline results for ROCCELLA phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
  • [6] Effectiveness and Implications of Alternative Placebo Treatments A Systematic Review and Network Meta-analysis of Osteoarthritis Trials
    Bannuru, Raveendhara R.
    McAlindon, Timothy E.
    Sullivan, Matthew C.
    Wong, John B.
    Kent, David M.
    Schmid, Christopher H.
    [J]. ANNALS OF INTERNAL MEDICINE, 2015, 163 (05) : 365 - U109
  • [7] Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity
    Berg, Kelly A.
    Clarke, William P.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (10) : 962 - 977
  • [8] Osteoarthritis subpopulations and implications for clinical trial design
    Bierma-Zeinstra, Sita M. A.
    Verhagen, Arianne P.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2011, 13 (02)
  • [9] Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis
    Brebion, Franck
    Gosmini, Romain
    Deprez, Pierre
    Varin, Marie
    Peixoto, Christophe
    Alvey, Luke
    Jary, Helene
    Bienvenu, Natacha
    Triballeau, Nicolas
    Blanque, Roland
    Cottereaux, Celine
    Christophe, Thierry
    Vandervoort, Nele
    Mollat, Patrick
    Touitou, Robert
    Leonard, Philip
    De Ceuninck, Frederic
    Botez, Iuliana
    Monjardet, Alain
    van der Aar, Ellen
    Amantini, David
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (06) : 2937 - 2952
  • [10] Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane
    Broeren, Mathijs G. A.
    de Vries, Marieke
    Bennink, Miranda B.
    Arntz, Onno J.
    van Lent, Peter L. E. M.
    van der Kraan, Peter M.
    van den Berg, Wim B.
    van den Hoogen, Frank H. J.
    Koenders, Marije I.
    van de Loo, Fons A. J.
    [J]. ARTHRITIS RESEARCH & THERAPY, 2016, 18
12345678910